复星医药：控股子公司获美国FDA药品临床试验批准

Group 1 - The core point of the article is that Fosun Pharma's subsidiary, Fuhong Hanlin, has received FDA approval to conduct a Phase I clinical trial for HLX43, a new drug aimed at treating thymic cancer [1] - Fuhong Hanlin plans to conduct global multi-center clinical research for this indication in Australia, Japan, and the United States once conditions are met [1] - The new drug is a targeted antibody-drug conjugate (ADC) developed by linking a novel DNA topoisomerase I inhibitor small molecule toxin-peptide chain conjugate with a self-developed PD-L1 targeted antibody, intended for the treatment of advanced/metastatic solid tumors [1] - As of June 2025, the total R&D investment for this new drug is approximately RMB 182 million [1]